Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1070806 in Moderate to Severe Atopic Dermatitis
NCT05999799Phase 2Terminated
- Sponsor
- GSK
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 2 trial of aletekitug in atopic dermatitis (AD), sponsored by GSK. Started Nov 2023; status: terminated.
02
Drugs
aletekitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05999799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999799.